CMS Grants Transitional Pass-Through Payment for Magtrace
The Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment to the Magtrace® lymphatic tracer, used in sentinel lymph node biopsy procedures.
Transitional pass-through payments are intended to provide additional payment for new devices, drugs, and biologicals that meet certain criteria and are intended to help enhance patient access to new technologies.
The approval of TPT means that Magtrace is eligible for reimbursement when administered in the hospital outpatient department for Medicare fee-for-service beneficiaries. Pass-through status is effective from January 1, 2025 for a period of three years.
Magtrace – now provided solely by Hologic in the US - is a non-radioactive, single injection dual-tracer used for sentinel lymph node mapping, providing a safe, effective and versatile approach to staging the axilla. It has been proven as non-inferior to the traditional ‘Gold Standard’ for SLNB - and provides further opportunities for the physician to streamline surgery.
“The approval of pass-through payment for Magtrace is a significant step forward in our mission to increase access to innovative breast cancer treatment,” said Eric Mayes, Vice President, General Manager.
“This decision acknowledges the growing adoption of Magtrace in the US, and will ensure that more women, can access advanced technologies that support better treatment outcomes.”Eric Mayes, Vice President, General Manager.
This latest milestone follows on from the approval of the Magtrace A9697 HCPCS code in October 2023, further strengthening its position as a leading non-radioactive alternative for breast cancer staging.
For any questions regarding reimbursement, contact: Hologic@thepinnaclehealthgroup.com | 1.866.369.9290
Pinnacle has been engaged for Endomag products and is cleared to handle any customer questions regarding TPT payment.